Johnson & Johnson Co-Leads $100 Million Round For Psychedelic Drug Developer
Johnson & Johnson's (NYSE: JNJ) venture capital arm has co-led a $100 million Series C financing round for psychedelic company Delix Therapeutics.
Johnson & Johnson's (NYSE: JNJ) venture capital arm has co-led a $100 million Series C financing round for psychedelic company Delix Therapeutics.
Nanox is revolutionizing medical imaging with its innovative digital X-ray technology and AI solutions, aiming to make imaging more accessible and affordable worldwide.
Stardust Power produces battery-grade lithium carbonate in the U.S., supporting the EV industry with sustainable and domestic supply chain solutions.
Ameresco, Inc. delivers energy efficiency and renewable solutions, helping organizations reduce costs, enhance reliability, and achieve sustainability goals.
KULR Technology delivers advanced thermal management and battery safety solutions for aerospace, defense, EVs, and energy storage systems.
Securitize provides blockchain-based tokenization, issuance, administration, and trading infrastructure for private markets and real-world financial assets.
Bitzero develops and operates data center infrastructure for high-performance computing, AI workloads, digital asset mining, and third-party hosting services.
The United States Nuclear Regulatory Commission has approved a construction permit for four X-energy (NASDAQ: XE) Xe-100 small modular reactors.
IBM (NYSE: IBM) has successfully deployed a Quantum System Two with their 120-qubit Nighthawk r2 processor at the University of Chicago’s Hyde Park Labs.
Neuroscientist and Stanford professor Andrew Huberman has officially joined the board of directors of Hims & Hers Health (NYSE: HIMS).
AST SpaceMobile (NASDAQ: ASTS) and Rakuten have formed a new joint venture to build a satellite network in Japan that connects directly to ordinary smartphones.
The New York Stock Exchange has selected Avalanche as the sole settlement ledger for their planned tokenized stock platform.
argenx (NASDAQ: ARGX) has entered into a definitive agreement to acquire oral-peptide discovery company Unnatural Products for up to $1.15 billion.
The markets and trends that matter, made simple.



Join top talent at the world's most respected institutions, companies, and venture capital funds.